22459-83-2

Upstream product

• 621-38-5 3-bromoacetanilide 
• 823-54-1 3-bromo-4-chloroaniline 
• 7647-01-0 hydrogenchloride 
• 64-17-5 ethanol 
• 29551-87-9 acetic acid-(3-bromo-N-chloro-anilide) 
• 7732-18-5 water 
• 64-19-7 acetic acid 
• 112160-74-4 acetic acid-(2,4,N-trichloro-anilide) 
• 75-36-5 acetyl chloride 
• 591-19-5 m-Bromoaniline 
• 103-84-4 Acetanilid 
• 539-03-7 N-(4-chlorophenyl)acetamide 
• 90050-43-4 Oxim des 3-Brom-4-chlor-acetophenons 

Downstream Products

• 823-54-1 3-bromo-4-chloroaniline 

Relevant academic research and scientific papers

Complementary Site-Selective Halogenation of Nitrogen-Containing (Hetero)Aromatics with Superacids

Site-selective functionalization of arenes that is complementary to classical aromatic substitution reactions remains a long-standing quest in organic synthesis. Exploiting the generation of halenium ion through oxidative process and the protonation of the nitrogen containing function in HF/SbF5, the chlorination and iodination of classically inert Csp2?H bonds of aromatic amines occurs. Furthermore, the superacid-promoted (poly)protonation of the molecules acts as a protection, favoring the late-stage selective halogenation of natural alkaloids and active pharmaceutical ingredients.

CHEMICAL COMPOUNDS

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormμLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be usefμL in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

A Visible Light-Mediated Regioselective Halogenation of Anilides and Quinolines by Using a Heterogeneous Cu-MnO Catalyst

A simple and practical heterogeneous Cu-MnO catalyzed regioselective halogenation of anilides and quinolines under irradiation with household 40 W incandescent lamp was developed. This method uses a recyclable Cu-MnO catalyst, acetonitrile as an industrially friendly solvent, and economic N-halo succinimides as a halogenating source. The reaction is scalable and well tolerated with a broad range of functional groups.

Imidazolium Salt Catalyzed para -Selective Halogenation of Electron-Rich Arenes

A highly para-selective halogenation of arenes bearing coordinating groups in the presence of a dimidazolium salt as a catalyst is reported. A series of electron-rich p-haloarenes were prepared in good yields and good to excellent selectivities. We also propose a plausible mechanism for the catalytic reaction.

Regioselective catalytic halogenation of aromatic substrates

Regioselective chlorination and bromination of some aromatic substances have been carried out using KCl and KBr in presence of sodium perborate as an oxidant and sodium metavanadate, sodium tungstate, ammonium metavanadate and ammonium molybdate as efficient catalysts. This environmentally friendly catalytic halogenation method gave good yields of products under mild conditions.